The suit has been filed in the U.S. District Court for the District of Columbia against Cephalon. According to the Commission, Cephalon, faced with threat to its Provigil monopoly, paid more than $200 million to generic drug companies to abandon their patent challenges and forgo entry into the market until April 2012. As Cephalon's CEO allegedly put it shortly after entering these settlements: "We were able to get six more years of patent protection. That's $4 billion in sales no one expected".
The FTC is clearly taking the issue very seriously, see also here.
-
Summary of DMA Review consultation, here. Submissions, here.
-
Euractiv, here. While some influential US/EU academics want us to largely forget the DMA and go back to a revised 102 😔.
-
TechPolicyPress, here. Good job, but I wouldn't call it controversy TBH.
-
Donotpassgo.ca, here.
-
R. Podszun, F. Scott Morton, here. I agree that more should be done in trying to make102 somewhat functional, but we aren't done with ...
-
Pressemeldung, hier .
-
LeParisien, ici.
-
Article 19, here (honoured that I could contribute to this).
No comments:
Post a Comment